Skip to main content
Research article - Peer-reviewed, 2021

Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma

Ulfstedt, Johan Mattsson; Venge, Per; Holmgren, Sofia; Enblad, Gunilla; Eriksson, Staffan; Molin, Daniel


Background: Thymidine kinase 1 (TK1) is an intracellular protein associated with DNA synthesis, expressed during the G1 phase and remained elevated through the M phase, with a potential as a biomarker for cell proliferation. In this study, we explore the possible use of TK1 in Hodgkin lymphoma (HL).Methods: Serum concentrations of TK1 (S-TK1) were measured in 46 newly diagnosed HL patients using prospectively collected biobanked serum samples. The samples were analyzed using a novel antibody-based TK1 immunosorbent assay (ELISA).Results: The concentrations of S-TK1 were elevated in HL patients compared with healthy controls (median 0.32 mu g/L vs. 0.24 mu g/L, P = 0.003). A further increase in S-TK1 was observed during the treatment. The S-TK1 concentrations were higher in patients with advanced stage disease, low B-Hb, elevated P-LD and in those with B-symptoms. A high ESR correlated with low S-TK1.Conclusions: The study results suggest that S-TK1, measured using a novel antibody-based assay, has the potential to be a biomarker in HL. However, while S-TK1 levels are elevated at baseline compared with healthy controls, a limited number of patients and comparatively short follow-up time render reliable -conclusions difficult.


Hodgkin lymphoma; TK1; Thymidine kinase; prognostic markers; chemotherapy

Published in

Upsala Journal of Medical Sciences
2021, volume: 126, number: 1, article number: e6119

Authors' information

Ulfstedt, Johan Mattsson
Uppsala University
Venge, Per
Uppsala University
Holmgren, Sofia
Diagnostics Development
Enblad, Gunilla
Uppsala University
Molin, Daniel
Uppsala University

UKÄ Subject classification

Immunology in the medical area

Publication Identifiers


URI (permanent link to this page)